GlaxoSmithKline's shingles vaccine filed in Europe
Most sufferers are afflicted with a rash, but in the severest cases the disease can cause blindness and intense pain.
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
749 stories · page 7 of 8
GlaxoSmithKline and Innoviva celebrate early FDA submission of COPD treatment
The closed triple combination therapy comprises three medicines delivered once-daily in GSK's Ellipta dry powder inhaler.
Risers and fallers: Fresnillo glistens, while Tate's in a state
Some of the main news-driven share price changes at 3.30pm.
Drugs stocks boosted by Clinton defeat
Markets have reacted badly to Trump's electoral victory, but some sectors have benefited
Archive
Brokers: UK pharma giants in good shape if Clinton wins says Citigroup
“From a legislative angle, we continue to prefer names with either limited part D exposure [US Medicare] or heavier contribution of non-pharma assets."
GlaxoSmithKline medicine goes down well in City
Deutsche analyst Richard Parkes said the market beating sales were mainly down to the group's strong sales of vaccines, notably for flu - Bexsero, Boostrix and Synflorix.
FTSE 100 stocks give up 7,000 level as miners come off on copper warning
FTSE 100 stocks gave up the 7,000 level on Wednesday as mining stocks dragged the market lower
Lloyds and a 'hard' Brexit in focus
Investors will be looking for any comment on a potential 'hard' Brexit in the Lloyds statement
US FDA approval for shingles vaccine eyed by Glaxo
The effects of the illness, a reactivation of the latent chickenpox virus, can be excruciating
GSK seeks US green light for shingles vaccine
"Shingles is a common and potentially serious condition,” said GSK’s head of vaccines, Dr Emmanuel Hanon.
Lloyds Banking and RBS to give post-Brexit vote updates
Britain's banks had enough on their plates already, but the Brexit vote made things more complicated still
GSK has been a Brexit winner, but can the FTSE share go higher?
As one of London's big 'dollar earners' it has been on the buy list for investors seeking Brexit winners.
Trending: Ashley's helicopter preference and new GSK boss
Mike Ashley’s interview with the BBC on how he runs Sports Direct this morning got the twittersphere buzzing.
GlaxoSmithKline's choice of new boss disappoints City
Shares fall after drug giant promotes boss of consumer healthcare division to top job
FTSE 100 closes higher, builds on previous day’s gains
UK shares closed higher on Tuesday, extending gains from the previous session, while investors awaited the outcome of central bank meetings in Japan and the United States
GlaxoSmithKline's shingles vaccine lasts four years in elderly patients
In a phase III study published in the New England Journal of Medicine, Shingrix showed a 90% efficacy in adults aged 70 and older that was maintained for four years.
Ocado gets another pasting over margin warning
Exane BNP Paribas downgrades online grocer after it warned of margin pressure from rivals
FTSE 100 closes firm as jobs, commodities buoy stocks
The FTSE 100, London’s blue-chip ticker, closed firm on Wednesday, buoyed by solid jobs data in the wake of Britain’s decision to leave the European Union and a surge by miners on rising commodity prices
UK stocks end lower on falling oil prices, sterling
London stocks end lower on Tuesday, pushed south by falling oil prices and a weaker sterling.
This unfancied drug stock has the potential to soar
There is a huge opportunity for the likes Vectura and is partner Hikma Pharmaceuticals as they copy-cat GlaxoSmithKline's asthma treatment.
GlaxosmithKline hails double drug successes
Drug giant reports upbeat results of lung disease and meningitis drug trials
UK shares surge, rub out previous day’s losses, as miners stage a comeback
London shares closed sharply higher on Friday and more than erased the previous session’s losses as two unlikely bedfellows – tobacco and pharma stocks – led the gains alongside a rebound by miners which had a difficult week
FTSE 100 sitting pretty ahead of US jobs report
An unlikely combination of tobacco and drugs stocks are driving the top-share index's advance
London shares end lower as PMI data reveals business costs rising
London shares ended lower on Thursday as a robust manufacturing survey was interpreted as adding to production costs, rather than boosting exports in the wake of Britain’s vote to leave the European Union
M Pharma's C-103 prevents Orlistat’s bowel-related side effects
M Pharmaceutical shares shot up more than 8% on Monday after the company released findings from the second of three proprietary pilot studies related to the recently acquired Chelatexx technology, referred to as the company's C-103 project
UK shares close lower, wary of Fed speech, pharma dragged down by Clinton remarks
London shares closed lower on Thursday, nestled in negative territory throughout the session, as investors turned wary ahead of Fed chair Janet Yellen’s speech at Jackson Hole on Friday and pharma stocks were singed by Hillary Clinton’s pro
Mylan boss take the fight to Hillary
Mylan reacted by announcing plans to boost access to the product by expanding already-existing programs for patients who face what’s called out-of-pocket expenses.
Shire leads the fallers as £3.7bn is wiped from drugs sector after Clinton blast
Hilary Clinton took aim at one US drugs company - yet the shock waves were felt here in London.
GlaxosmithKline teams up with Google sister firm in bioelectronics venture
Drug giant is setting up a new company, Galvani Bioelectronics, with Verily Life Sciences
UK shares end softer as demand surges for gilts on rate cut talk
London's blue-chip stocks ended lower on Thursday after a session spent mostly suspended beneath the previous closing level as investors sought safer haven in UK government bonds, or gilts
Banking and oil woe drags FTSE 100 Index lower
The FTSE 100 Index was 6.56 points adrift at 6,743.87 in lunchtime trading
Footsie treads water amid negative news from Lloyds
The FTSE 100 Index was 3.2 points adrift at 6,747.24 in early trading
Builders and building materials
UK shares rise as a session of superlatives grips the City
London blue-chip shares closed Wednesday at a more than one-year high, AIM paper had its best level in over two years, and mid-caps briefly beat pre-Brexit levels
Footsie perks up after shot in arm from Glaxosmithkline
Shares in GSK rose 25p, or 1.5%, to 1692p after it reported a 4% rise in group sales to £6.5bn
GlaxoSmithKline upbeat despite currency hit
Sales rose by 4% in constant currencies and 11% in sterling terms to £6.5bn in the latest quarter.
Investments and investor services
FTSE 100 Index rises on upbeat economic data
The FTSE 100 Index rose 16.8 points to 6740.83 as second quarter UK GDP growth rose
PREVIEW: Investors hoping Apple will bear fruit
Maker of iPhone likely to report slower device sales although services are tipped to have done well
London blue chips sag but takeover talk buoys midcaps
London shares ended lower on Monday, as the weight of negative economic data finally overwhelmed a market propped up earlier in the session by takeover talk
Takeover news boosts stocks despite more economic woe
William Hill gets takeover approach from Rank Group and 888
Investments and investor services
FTSE 100 Index rises ahead of busy week
The FTSE 100 Index picked up 22.9 points to 6753.39
WEEK AHEAD: Blue-chips aplenty due to update market
The first of the big companies reports on Tuesday when BP PLC (LON:BP.) issues a trading statement
Archive
GlaxoSmithKline given a shot in the arm by Jefferies
Jefrey Holford, analyst, believes that the group's 4.9% dividend yield is becoming increasingly well covered..
FTSE 100 closes above Brexit crisis levels
London’s FTSE 100 index on Wednesday closed above “Brexit” crisis levels for the first time since the morning of the In-Out European Union referendum polling last Thursday
Glaxo/Innoviva triple combo COPD treatment passes phase III
“By combining three medicines in a single inhaler we can offer a convenient, once-daily dosing option to patients while improving their symptoms."
The Footsie treads water as it awaits US jobs report
Today's two big economic events - the ECB and Opec meetings - proved about as decisive as an Italian election, so all eyes now move to tomorrow's US jobs report.
Footsie rises as Opec meets while drug bid talk swirls
The Footsie rose and drug industry takeover talk provided interest
Innoviva hails progress with lung disease treatment
British and US health groups report positive results from chronic obstructive pulmonary disease study
Glaxosmithkline meningitis vaccine achieves endpoints
GSK's meningitis vaccine achieved the primary and secondary endpoints.
Archive
No jumps on the way for William Hill, says Canaccord
Bookmaker William Hill has its target lowered by City broker Canaccord.....
Redx hires new director
Redx Pharma welcomes experienced pharma and biotech executive as director
PREVIEW: Can AstraZeneca follow Glaxo with better-than-expected quarterlies?
AstraZeneca releases first quarter results on Friday, the schedule also includes Shire, BA owner International Consolidated Airlines, and Royal Bank of Scotland Group.
GlaxoSmithKline recovery on track claims chief
Sales and underlying profits were both ahead of market forecasts
FTSE 100, small caps rally as big names reassure
London markets recovered from a lacklustre start and were pushing on
Week Ahead: Investors look out for Apple, Twitter, Facebook and BP results
After Silicon Valley giants Alphabet and Microsoft disappointed this week, next Tuesday brings Apple Inc’s second-quarter earnings.
ABInBev and SABMiller sell Peroni to Japan's Asahi
ABInBev and SABMiller are also off-loading Grolsch and Meantime
Investments and investor services
Goldman Sachs’ bets are off William Hill Plc
William Hill, Poundland, Mothercare, Stock Spirits, and GlaxoSmithKline are all in Friday’s broker spotlight.
Investments and investor services
Stocks advance, led by Botswana Diamonds PLC and Cyan Holdings PLC
Throughout the day Botswana Diamonds and Cyan Holdings competed to be the biggest riser on the day.
Archive
Brokers: Jefferies foresees fall in consumer confidence
Lots of dark clouds are gathering for retailers, judging by the latest retail review from Jefferies. Also covered: GlaxoSmithKline, Aureus Mining, Spire Healthcare Group
Most followed: Donald Trump, Gulf Keystone Ltd, GlaxoSmithKline, Rio Tinto, Sirius Minerals, Tesco
Tesco managers told to be nicer, Donald Trump a 'global risk' and FTSE 100 casualties.
GlaxoSmithKline PLC boss to quit in 2017 amid shake-up talk
Drug giant says Andrew Witty will go in March 2017
Archive
AstraZeneca PLC lacks catalysts for 2016 - Jefferies
Broker Jefferies has cut its rating on drugs giant AstraZeneca PLC to 'hold' from 'buy' saying there's a lack of catalysts in 2016 to re-rate shares.
FTSE 100 closes Monday’s trading flat
The blue-chip benchmark ended February a solitary point higher than Friday’s closing price.
London market moves lower but investors shop at Morrisons
The FTSE 100 Index dropped due to China’s slowdown, Brexit fears and commodity uncertainty
GlaxoSmithKline launches hunt for new chief executive
Drug group is said to have kicked off succession planning, but it is in no rush to replace Witty
OR Productivity lines up pre-IPO funding
OR Productivity aims to become a go-to company for the commercialisation of minimally invasive medicine
Archive
Footsie closes lower as oil and Standard Chartered weigh
Footsie closed 1.25% down as oil weighed along with the results from Standard Chartered..
London shares fall on mining woe and business's EU exit fears
Footsie companies warned that EU exit could cost UK jobs and investment
Archive
Jefferies downgrades targets on Glaxo and Astra
US heavyweight Jefferies looks at global pharma today and downgraded Glaxo and AstraZeneca...
Archive
FTSE 100 makes good ground despite Brexit talk
Footsie was buoyed by a good start to the week;s trading on Wall Street
FTSE100 posts solid gains as Brexit talks slays sterling
FTSE 100 climbed 76 points to 6,026 despite a tough day for the pound
Glaxo fined £38mln for Seroxat deal 15 years ago
The CMA levied the £45mln penalties for ‘pay and delay’ agreements
Archive
FTSE100 finishes down as Lloyds slashes jobs
FTSE100 continued lower on Wednesday to finish almost 1.5% lower..
GlaxoSmithKline gets shot in arm but M&A talk trundles on
Drug company boosted 2015 revenues and achieved better-than-expected dip in earnings
Shares below 5,900 on Asian and Europe economic woes
The FTSE 100 Index, which was 16 points off in earlier trading, fell below the 5900 level
GlaxoSmithKline earnings fall but on track to save £3bn
Drug company confirmed a 2015 ordinary dividend of 80p and special payout of 20p per share
London shares fall after Asian markets end in red
The Footsie fell 16.18 points to 5905 but GlaxoSmithKline got a boost from M&A rumours
Week Ahead: Big oil and big pharma to the fore
Big oil and big pharma will wrestle for the limelight. On the economic front, the big events are the Bank of England's interest rate decision and US non-farm payrolls.
Archive
FTSE100 falls as oil hopes rise; Glaxo bid talk swirls
Britain's blue chips closed the afternoon session lower after uninspiring UK economic data and as energy powerhouse Centrica weighed.
Trending: Johnson & Johnson mulling Glaxo bid?
Open Outcrier tweets that there is “vague takeover chatter” concerning a takeover of drugs giant GlaxoSmithKline by healthcare behemoth Johnson & Johnson.
Archive
JP Morgan prefers precious metals over bulks
Heavyweight JP Morgan Cazenove becomes the latest house to paint a gloomy picture for mining stocks in 2016 but says it prefers precious metals to bulk commodities in a note on Monday.
Archive
Barclays pharma experts bullish on Shire and Glaxo
Shares in drug giants Glaxo and Shire should stay in fine heath this year, Barclays says
FTSE100 falls but bid talk lifts Smith & Nephew
Santa rally hopes faded but S&N takeover chatter provided interest
FTSE100 eases; Glaxo buys HIV assets
The FTSE100 lost around 36 points to 6,605 by lunch after three consecutive days of gains.
FTSE rises; Supergroup makes a super start to the year
The FTSE100, which is down around 7.5% on the year, rose almost 1%, or 59 points, to 6,076 by lunch.
Investments and investor services
FTSE100 moves firmly away from three-year lows
The index appears likely to end its run of eight straight daily falls,
FTSE100 registers triple digit gains
The index appears likely to end its run of eight straight daily falls,
Investments and investor services
FTSE100 rally gives investors something to cheer
The FTSE 100 Index was around 1.5%, or 90 points, higher to 5,964
Investments and investor services
FTSE100 gains 25, Shire rises on M&A chatter
The FTSE100 could only manage a 25 point gain to 6,420.
FTSE 100 consolidates early gains
FTSE 100 was 21 points higher at 6,416 ahed of the US opening
GlaxoSmithKline pins future on 40 new drugs
The UK pharma giant may file up to 20 treatments with regulators before 2020.
Archive
Deutsche upbeat on Glaxo; lifts price target
Broker heavyweight Deutsche is upbeat on drugs giant GlaxoSmithKline on Friday and has punted up the target price to 1,500p from 1,450p.
Investments and investor services
Glaxo's study results more bad than good reckons JP Morgan
Strong Phase III data for its Shingrix shingles vaccine in patients over 70 years follow encouraging data from the 50 years and older study.
Investments and investor services
FTSE 100 gets afternoon boost from Glaxo
Stocks were on an upward trend, helped by a recovery by commodity plays